SeekIn Presents New OncoSeek® Data at the AACR Annual Meeting in San Diego
SAN DIEGO, April 8, 2024 /PRNewswire/ -- SeekIn Inc., a leader in blood-based cancer early detection and monitoring technology, today announced three additional validation studies that evaluate OncoSeek's ability to detect more than nine cancer types and predict the tissue of origin with a tube of blood. The data further validate the performance of OncoSeek with consistent results between the three new cohorts and the three previous cohorts of ~12,000 participants from China, the United States and Brazil. The results from three different platforms and two sample types indicate the generalization of OncoSeek's capability for common protein marker platforms. The findings were presented at the session entitled 'Multi-Cancer Early Detection Testing: Where Are We?' at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, one of the most significant oncology conferences highlighting the work of the best minds in cancer research from institutions all over the world.
- The results from three different platforms and two sample types indicate the generalization of OncoSeek's capability for common protein marker platforms.
- The findings were presented at the session entitled 'Multi-Cancer Early Detection Testing: Where Are We?'
- at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, one of the most significant oncology conferences highlighting the work of the best minds in cancer research from institutions all over the world.
- With the demonstrated performance of OncoSeek on retrospective and prospective cohorts, SeekIn is pursuing additional prospective studies to evaluate performance in different applications.